Find your next quality investment with Simply Wall St's easy and powerful screener, trusted by over 7 million individual investors worldwide. DexCom (NasdaqGS:DXCM) has begun a broad U.S. rollout of ...

BTIG analysts continue to expect growth from Dexcom (Nasdaq:DXCM) after meeting with the company's senior investor relations (IR) officials.

The US FDA has cleared a new “basal insulin dose optimizer” function for the Dexcom G7 15-day continuous glucose monitor (CGM), which is set to launch separately on December 1, 2025. The “Smart Basal” ...

In his inaugural J.P. Morgan Healthcare Conference speech, newly minted Dexcom CEO Jake Leach looked to ease concerns over last year's supply shortage of the company's leading diabetes product. Leach ...

デクスコムジャパン合同会社（本社：東京都目黒区、日本法人社長 浅野 元）は本日、リアルタイムCGM「Dexcom G7 CGMシステム」を発売しました。本製品は2023年9月に製造販売承認を得ており、糖尿病のある方で2歳以上のインスリン自己注射を1日に1回以上行っ ...

DexCom Inc. (NASDAQ:DXCM) is one of the best growth stocks to buy in 2026. On December 2, Morgan Stanley upgraded DexCom to Overweight from Equal Weight with a price target of $75, which was up from ...

Dexcom G7 15 Day will first be available through durable medical equipment (DME) providers with full retail launch in the coming weeks. Designed to provide real-time glucose readings for an ...

～高精度で小型化、起動時間を短縮し、使いやすさの向上を目指したデバイス～ デクスコムジャパン合同会社（本社：東京都目黒区、日本法人社長 浅野 元）は本日、リアルタイムCGM「Dexcom G7 CGMシステム」を発売しました。本製品は2023年9月に製造販売承認 ...

Looking ahead to 2026, DexCom projects total revenue between $5.16 billion and $5.25 billion, representing expected growth of approximately 11-13% over 2025. The company also provided guidance for ...